Tafenoquine

Tafenoquine
	File:Tafenoquine.svg
Identifiers
	IUPAC name N-[2,6-dimethoxy-4-methyl-5-[3-(trifluoromethyl); phenoxy]quinolin-8-yl]pentane-1,4-diamine;
CAS Number	106635-80-7;
PubChem CID	115358;
E number	{{#property:P628}}
ECHA InfoCard	{{#property:P2566}}Lua error in Module:EditAtWikidata at line 36: attempt to index field 'wikibase' (a nil value).
Chemical and physical data
Formula	C24H28F3N3O3
Molar mass	463.493 g/mol

Tafenoquine (also called WR-238605 or SB-252263) is an 8-aminoquinoline drug manufactured by GlaxoSmithKline that is currently being investigated as a potential treatment for malaria, as well as for malaria prevention.^[1]^[2]

The main advantage of tafenoquine is that it has a long half-life and therefore does not need to be taken as frequently as primaquine. Like primaquine, tafenoquine causes haemolysis in people with G-6-PD deficiency.^[1]

The dose of tafenoquine has not been firmly established, but for the treatment of Plasmodium vivax malaria, a dose of 800 mg over three days has been used.^[3]

References

↑ ^1.0 ^1.1 Shanks GD, Oloo AJ, Aleman GM; et al. (2001). "A New Primaquine Analogue, Tafenoquine (WR 238605), for prophylaxis against Plasmodium falciparum malaria". Clin Infect Dis. 33: 1968&ndash, 74.
↑ Lell B, Faucher JF, Missinou MA; et al. (2000). "Malaria chemoprophylaxis with tafenoquine: a randomised study". Lancet. 355 (9220): 2041&ndash, 5. PMID 10885356.
↑ Nasvelda P, Kitchener S. (2005). "Treatment of acute vivax malaria with tafenoquine". Trans R Soc Trop Med Hyg. 99 (1): 2&ndash, 5. doi:10.1016/j.trstmh.2004.01.013.

This antimicrobial-related article is a stub. You can help Wikipedia by expanding it.

Template:WikiDoc Sources

[Shanks2001-1] 1.0 ^1.1 Shanks GD, Oloo AJ, Aleman GM; et al. (2001). "A New Primaquine Analogue, Tafenoquine (WR 238605), for prophylaxis against Plasmodium falciparum malaria". Clin Infect Dis. 33: 1968&ndash, 74.

[2] Lell B, Faucher JF, Missinou MA; et al. (2000). "Malaria chemoprophylaxis with tafenoquine: a randomised study". Lancet. 355 (9220): 2041&ndash, 5. PMID 10885356.

[3] Nasvelda P, Kitchener S. (2005). "Treatment of acute vivax malaria with tafenoquine". Trans R Soc Trop Med Hyg. 99 (1): 2&ndash, 5. doi:10.1016/j.trstmh.2004.01.013.

[1]

[2]

[3]

Identifiers
File:Tafenoquine.svg
IUPAC name N-[2,6-dimethoxy-4-methyl-5-[3-(trifluoromethyl) phenoxy]quinolin-8-yl]pentane-1,4-diamine
CAS Number	106635-80-7
PubChem CID	115358
E number	{{#property:P628}}
ECHA InfoCard	{{#property:P2566}}Lua error in Module:EditAtWikidata at line 36: attempt to index field 'wikibase' (a nil value).
Chemical and physical data
Formula	C₂₄H₂₈F₃N₃O₃
Molar mass	463.493 g/mol

Tafenoquine

References

Navigation menu